Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of EUR 759.87 million. The enterprise value is 782.30 million.
| Market Cap | 759.87M | 
| Enterprise Value | 782.30M | 
Important Dates
The next estimated earnings date is Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 | 
| Ex-Dividend Date | n/a | 
Share Statistics
Nanobiotix has 48.22 million shares outstanding. The number of shares has increased by 10.33% in one year.
| Current Share Class | 48.22M | 
| Shares Outstanding | 48.22M | 
| Shares Change (YoY) | +10.33% | 
| Shares Change (QoQ) | +0.03% | 
| Owned by Insiders (%) | 3.30% | 
| Owned by Institutions (%) | 6.00% | 
| Float | 30.86M | 
Valuation Ratios
| PE Ratio | n/a | 
| Forward PE | n/a | 
| PS Ratio | 74.80 | 
| PB Ratio | -11.02 | 
| P/TBV Ratio | n/a | 
| P/FCF Ratio | n/a | 
| P/OCF Ratio | n/a | 
| PEG Ratio | n/a | 
Enterprise Valuation
| EV / Earnings | -15.15 | 
| EV / Sales | 77.01 | 
| EV / EBITDA | n/a | 
| EV / EBIT | n/a | 
| EV / FCF | -24.73 | 
Financial Position
The company has a current ratio of 0.63
| Current Ratio | 0.63 | 
| Quick Ratio | 0.58 | 
| Debt / Equity | n/a | 
| Debt / EBITDA | n/a | 
| Debt / FCF | -1.62 | 
| Interest Coverage | -5.19 | 
Financial Efficiency
| Return on Equity (ROE) | n/a | 
| Return on Assets (ROA) | -41.64% | 
| Return on Invested Capital (ROIC) | -567.28% | 
| Return on Capital Employed (ROCE) | 245.90% | 
| Revenue Per Employee | 98,631 | 
| Profits Per Employee | -501,388 | 
| Employee Count | 108 | 
| Asset Turnover | 0.15 | 
| Inventory Turnover | n/a | 
Taxes
| Income Tax | -37,000 | 
| Effective Tax Rate | n/a | 
Stock Price Statistics
The stock price has increased by +310.58% in the last 52 weeks. The beta is 0.48, so Nanobiotix's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 | 
| 52-Week Price Change | +310.58% | 
| 50-Day Moving Average | 14.18 | 
| 200-Day Moving Average | 6.58 | 
| Relative Strength Index (RSI) | 45.87 | 
| Average Volume (20 Days) | 852,703 | 
Short Selling Information
| Short Interest | n/a | 
| Short Previous Month | n/a | 
| Short % of Shares Out | n/a | 
| Short % of Float | n/a | 
| Short Ratio (days to cover) | n/a | 
Income Statement
In the last 12 months, Nanobiotix had revenue of EUR 10.16 million and -51.64 million in losses. Loss per share was -1.09.
| Revenue | 10.16M | 
| Gross Profit | 10.16M | 
| Operating Income | -43.93M | 
| Pretax Income | -51.68M | 
| Net Income | -51.64M | 
| EBITDA | -43.84M | 
| EBIT | -43.93M | 
| Loss Per Share | -1.09 | 
Balance Sheet
The company has 28.82 million in cash and 51.24 million in debt, giving a net cash position of -22.42 million or -0.47 per share.
| Cash & Cash Equivalents | 28.82M | 
| Total Debt | 51.24M | 
| Net Cash | -22.42M | 
| Net Cash Per Share | -0.47 | 
| Equity (Book Value) | -68.95M | 
| Book Value Per Share | -1.43 | 
| Working Capital | -23.15M | 
Cash Flow
In the last 12 months, operating cash flow was -31.13 million and capital expenditures -507,000, giving a free cash flow of -31.63 million.
| Operating Cash Flow | -31.13M | 
| Capital Expenditures | -507,000 | 
| Free Cash Flow | -31.63M | 
| FCF Per Share | -0.66 | 
Margins
| Gross Margin | 100.00% | 
| Operating Margin | -432.39% | 
| Pretax Margin | -508.71% | 
| Profit Margin | n/a | 
| EBITDA Margin | n/a | 
| EBIT Margin | n/a | 
| FCF Margin | n/a | 
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a | 
| Dividend Yield | n/a | 
| Dividend Growth (YoY) | n/a | 
| Years of Dividend Growth | n/a | 
| Payout Ratio | n/a | 
| Buyback Yield | -10.33% | 
| Shareholder Yield | -10.33% | 
| Earnings Yield | -6.80% | 
| FCF Yield | -4.16% | 
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a | 
| Lynch Upside | n/a | 
| Graham Number | n/a | 
| Graham Upside | n/a | 
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a | 
| Split Type | n/a | 
| Split Ratio | n/a | 
Scores
Nanobiotix has an Altman Z-Score of -2.82 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.82 | 
| Piotroski F-Score | 1 |